Why the study?
The utility of TEVAR in TBAD is advancing rapidly, prompting evaluation of institutional management strategies and early- to mid-term outcomes at a single tertiary center.
What are the early and mid-term outcomes of thoracic endovascular aortic repair (TEVAR) in patients with Type B Aortic Dissection?
What are the early and mid-term outcomes of thoracic endovascular aortic repair (TEVAR) in patients with Type B Aortic Dissection?
TEVAR for Type B aortic dissection demonstrates high technical success and acceptable early mortality, supporting its use particularly when patients can be bridged to the subacute phase.
Answers are grounded in this paper and cite their sources.
TEVAR was associated with high technical success and acceptable mortality in Type B dissection; supports selected use but leaves open randomized confirmation.
Aim: The utility of thoracic endovascular aortic repair (TEVAR) in Type B Aortic dissections (TBAD) continues to advance at a growing rate. The purpose of this research was to investigate our management strategy and early-mid-term outcomes of endovascular procedures for TBAD, in a single tertiary center. Material and Methods: Sixty-six eligible TBAD patients (2 hyperacute complicated, 12 acute complicated and 52 uncomplicated) were enrolled in this single-center, retrospective cohort study between January 2016 and January 2023. The endpoints of the study were technical success, early and late morbidity and mortality, reinterventions throughout the follow-up period, as well as late open conversion. Results: Technical success was achieved in all cases. Early mortality was seen in only 3 patients (4.5%). Only patients with one hyperacute and two acute complicated TBAD (cTBAD) had early death. There was one late mortality in an acute cTBAD patient, who developed retrograde type A dissection two months after TEVAR. The median follow-up period was 26.1±13.7 months. Six reinterventions were performed for extension of dissection or covering the entries distally (9.1%). No endoleak, graft infection or migration were observed. Open surgical repair was performed; however, the patient did not survive. Conclusion: Early results of TEVAR in elective TBAD is trouble-free. Carrying the patients to the subacute phase seems to be the most suitable timing for TEVAR. Anti-stimulus and anti-hypertensive treatment with surveillance programme is mandatory for this patient cohort. Pre-emptive TEVAR has satisfactory results; however, long-term results are mandatory for further recommendations.
No takes yet. Share an insight, caveat, or question.
Yiğit et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: